安杰思成立于2010年12月6日，于2023年5月19日在上海证券交易所上市，注册地和办公地均为浙江省杭州 市。该公司是国产内镜诊疗耗材龙头之一，专注于内镜微创诊疗器械的研发、生产与销售，具备技术创新 和产品差异化优势。 经营业绩：营收行业第31，净利润第21 2025年三季度，安杰思营业收入为4.59亿元，在行业50家公司中排名第31。行业第一名英科医疗营收74.25 亿元，第二名国科恒泰营收53.53亿元，行业平均数为13.79亿元，中位数为7.55亿元。当期净利润为1.77亿 元，行业排名第21。行业第一名乐普医疗净利润9.96亿元，第二名英科医疗净利润9.52亿元，行业平均数 为1.83亿元，中位数为7588.01万元。 资产负债率远低于同业平均，毛利率高于同业平均 偿债能力方面，2025年三季度安杰思资产负债率为4.17%，去年同期为4.67%，远低于行业平均的23.66%， 显示出良好的偿债能力。从盈利能力看，2025年三季度毛利率为70.51%，去年同期为72.13%，高于行业平 均的48.78%，盈利能力较强。 董事长张承薪酬365.89万元，同比增加35.9万元 公司控股股东为杭州一嘉投资管 ...

Core Viewpoint - Anjiasi's stock has experienced a decline recently, with a notable drop in trading volume and a mixed performance in revenue and profit growth [1][2]. Company Overview - Anjiasi Medical Technology Co., Ltd. was established on December 6, 2010, and went public on May 19, 2023. The company is based in Hangzhou, Zhejiang Province, and specializes in the research, development, production, and sales of minimally invasive diagnostic and therapeutic instruments [1]. - The main business revenue composition is as follows: GI category 62.74%, EMR/ESD category 23.26%, ERCP category 11.04%, instruments category 2.21%, and others 0.74% [1]. Financial Performance - For the period from January to September 2025, Anjiasi achieved operating revenue of 459 million yuan, representing a year-on-year growth of 7.51%. However, the net profit attributable to the parent company was 177 million yuan, showing a year-on-year decrease of 10.35% [2]. - Since its A-share listing, Anjiasi has distributed a total of 239 million yuan in dividends [3]. Shareholder Information - As of October 20, 2025, the number of shareholders for Anjiasi was 5,728, an increase of 2.89% from the previous period. The average circulating shares per person decreased by 2.47% to 7,255 shares [2]. - Notable new institutional shareholders include Ping An Low Carbon Economy Mixed A (009878) as the fourth largest shareholder with 850,000 shares, and Hong Kong Central Clearing Limited as the eighth largest shareholder with 420,900 shares [3].

Group 1 - China Satellite reported a net profit of 14.81 million yuan for the first three quarters, marking a turnaround from losses, with a revenue of 3.102 billion yuan, up 85.28% year-on-year [1] - SAIYANG Technology signed a contract worth 533 million yuan for Airbus A320 series aircraft transport tooling, effective until 2038 [1] - Zhongwei Semiconductor achieved a net profit of 152 million yuan, a 36.78% increase year-on-year, with a revenue of 773 million yuan, up 19.03% [2] Group 2 - Jiao Cheng Ultrasonic reported a net profit of 94.03 million yuan, a significant increase of 359.81% year-on-year, with a revenue of 521 million yuan, up 27.53% [3] - Keda Li's net profit grew by 16.55% year-on-year to 1.185 billion yuan, with a revenue of 10.603 billion yuan, up 23.41% [3] - Ningbo Huaxiang's net profit fell by 87.68% to 88.73 million yuan, despite a revenue increase of 5.88% to 19.224 billion yuan [4] Group 3 - Mingzhi Electric reported a net profit of 49.84 million yuan, a 5.43% increase year-on-year, with a revenue of 2.043 billion yuan, up 11.66% [6] - Xianda Co. achieved a net profit of 196 million yuan, a staggering increase of 3064.56% year-on-year, with a revenue of 2.008 billion yuan, up 6.11% [7] - Longxin General's net profit rose by 75.45% to 1.577 billion yuan, with a revenue of 14.557 billion yuan, up 19.14% [8] Group 4 - Hainan Highway reported a net loss of 10.63 million yuan, despite a revenue increase of 133.41% to 314 million yuan [9] - Zhongci Electronics achieved a net profit of 443 million yuan, a 20.07% increase year-on-year, with a revenue of 2.143 billion yuan, up 13.62% [11] - Hangyang Co. reported a net profit of 757 million yuan, a 12.14% increase year-on-year, with a revenue of 11.428 billion yuan, up 10.39% [12] Group 5 - Yuanli Technology's net profit decreased by 2.89% to 152 million yuan, with a revenue of 1.654 billion yuan, down 3.69% [13] - Guihang Co. reported a net profit of 118 million yuan, a slight increase of 0.77%, with a revenue of 1.870 billion yuan, up 8.65% [14] - Haixing Co. achieved a net profit of 147 million yuan, a 41.41% increase year-on-year, with a revenue of 1.711 billion yuan, up 21.45% [16] Group 6 - Weiteng Electric reported a net profit decline of 87.47% to 13.66 million yuan, with a revenue of 2.597 billion yuan, down 5.40% [18] - Tiancai Control achieved a net profit of 50.33 million yuan, a 91.73% increase year-on-year, with a revenue of 1.855 billion yuan, up 27.3% [20] - Hangzhi Qianjin reported a net profit of 207 million yuan, a 9.59% increase year-on-year, with a revenue of 1.730 billion yuan, up 5.39% [21] Group 7 - Suli Co. reported a net profit of 139 million yuan, a remarkable increase of 1522.38%, with a revenue of 2.064 billion yuan, up 25.39% [23] - Sanqi Interactive achieved a net profit of 2.345 billion yuan, a 23.57% increase year-on-year, with a revenue of 12.461 billion yuan, down 6.59% [24] - Yongjie New Materials reported a net profit of 309 million yuan, a 30.99% increase year-on-year, with a revenue of 7.020 billion yuan, up 20.01% [26] Group 8 - Kang Enbei achieved a net profit of 584 million yuan, a 12.65% increase year-on-year, with a revenue of 4.976 billion yuan, up 1.27% [28] - Zhongyuan Highway reported a net profit of 961 million yuan, a 16.78% increase year-on-year, with a revenue of 4.888 billion yuan, up 3.89% [30] - Hunan Gold achieved a net profit of 1.029 billion yuan, a 54.28% increase year-on-year, with a revenue of 41.194 billion yuan, up 96.26% [32] Group 9 - Huadong Pharmaceutical reported a net profit of 2.748 billion yuan, a 7.24% increase year-on-year, with a revenue of 32.664 billion yuan, up 3.77% [33] - Dongyangguang achieved a net profit of 906 million yuan, a significant increase of 189.80%, with a revenue of 10.970 billion yuan, up 23.56% [35] - Xinrui Technology reported a net loss of 62.62 million yuan, despite a revenue increase of 28.02% to 1.672 billion yuan [37] Group 10 - Jiabiyou achieved a net profit of 129 million yuan, a 54.18% increase year-on-year, with a revenue of 428 million yuan, up 10.56% [38] - Ruifeng New Materials reported a net profit of 574 million yuan, a 14.85% increase year-on-year, with a revenue of 2.551 billion yuan, up 10.87% [39] - Zhongfu Industrial achieved a net profit of 1.187 billion yuan, a 63.25% increase year-on-year, with a revenue of 16.633 billion yuan, down 0.60% [40] Group 11 - Aohai Technology reported a net profit of 359 million yuan, a 19.32% increase year-on-year, with a revenue of 5.188 billion yuan, up 14.14% [41] - Kangzhong Medical announced a share transfer plan involving 5.33% of its shares due to shareholder funding needs [43] - Hualing Steel plans to invest 512 million yuan in a new continuous casting project [44]

Core Viewpoint - The company, Hangzhou Anjisi Medical Technology Co., Ltd., has released its quarterly report, ensuring the accuracy and completeness of the financial information presented, and confirming that there are no false records or significant omissions [2][3]. Financial Data Summary - The financial statements for the third quarter are unaudited, covering the period from the beginning to the end of the quarter [3][7]. - The report includes major accounting data and financial indicators, although specific figures are not detailed in the provided text [3]. - The company has not recognized any non-recurring gains or losses that are significant, and there are no changes in the classification of recurring and non-recurring items [4][5]. Shareholder Information - The report includes information on the total number of ordinary shareholders and the top ten shareholders, although specific numbers are not provided [5][6]. - There are no changes reported regarding the participation of major shareholders in securities lending activities [6]. Other Important Information - The company has confirmed that it will not apply new accounting standards or interpretations that would affect the financial statements for the current reporting period [7].

格隆汇10月27日丨安杰思(688581.SH)发布三季报，2025年前三季度实现营业总收入4.59亿元，同比增长 7.51%；归属母公司股东净利润1.77亿元，同比下降10.35%；基本每股收益为2.18元。 ...

Group 1 - The core viewpoint of the article highlights that Anjisi (SH 688581) reported its third-quarter performance, showing a revenue increase but a decline in net profit [1] Group 2 - For the third quarter of 2023, Anjisi's revenue was approximately 459 million yuan, representing a year-on-year increase of 7.51% [1] - The net profit attributable to shareholders was about 177 million yuan, reflecting a year-on-year decrease of 10.35% [1] - As of the report date, Anjisi's market capitalization stood at 5.4 billion yuan [2]

杭州安杰思医学科技股份有限公司 2025 年第三季度报告 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 证券代码：688581 证券简称：安杰思 杭州安杰思医学科技股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 单位：元 币种：人民币 | | | 本报告期比 | | 年初至报告期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 156,896,637.59 | -3.89% | ...

一、减持主体减持前基本情况 ■ 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●股东持有的基本情况 本次减持计划实施前，公司苏州元生私募基金管理合伙企业（有限合伙）－苏州工业园区新建元二期创 业投资企业（有限合伙）（以下简称"新建元"）持有3,233,835股，占公司总股本的3.9934%，其中持有 的股份来源为公司首发前股份数2,309,882股，通过公司2023年年度派送红股获得的股份数923,953股。 上述股东持有的公司首发前股份已于2024年5月20日解除限售并上市流通。 ●减持计划的实施结果情况 2025年7月3日，公司于上海证券交易所网站（www.sse.com.cn）披露了《杭州安杰思医学科技股份有限 公司股东减持股份计划公告》（公告编号：2025-045）。因企业自身的经营安排，股东新建元拟合计减 持公司股份不超过1,622,700股（即不超过公司股份总数的2.0039%），其中，通过集中竞价交易方式减 持不超过809,700股；通过大宗交易方式减持不超过813,000股，拟减 ...

格隆汇10月23日丨安杰思(688581.SH)公布，2025年10月23日，公司收到股东新建元出具的《减持结果 告知函》，截至2025年10月23日，股东新建元通过集中竞价交易方式减持34.58万股，占总股本的 0.4270%；通过大宗交易方式减持0股，占总股本的0.000%，合计减持34.58万股，占总股本的0.4270%， 本次减持计划结束。 ...

Group 1 - The core point of the news is that Anjisi (SH 688581) announced the completion of a share reduction plan by its shareholder, Xinjianyuan, who reduced approximately 350,000 shares, accounting for 0.427% of the total share capital [1] - As of October 23, 2025, Xinjianyuan reduced shares through centralized bidding, totaling about 350,000 shares, with no shares reduced through block trading [1] - For the year 2024, Anjisi's revenue composition is heavily weighted towards medical devices, which account for 99.41% of total revenue, while other businesses contribute only 0.59% [1] Group 2 - As of the latest report, Anjisi's market capitalization stands at 5.3 billion yuan [2] - The Chinese innovative drug sector has seen significant overseas licensing deals, totaling $80 billion this year, indicating a robust secondary market for biomedicine [2] - Despite the hot secondary market, the primary market for fundraising in the biomedicine sector is experiencing a cooling trend, as noted by a partner at a venture capital firm [2]